Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial
Clinical and Experimental Ophthalmology, Volume 50, No. 9, Year 2022
Notification
URL copied to clipboard!
Description
Background: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia-control approach in Australian children. Methods: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into this single-centre randomised, parallel, double-masked, placebo-controlled trial and randomised to receive 0.01% atropine (n = 104) or placebo (n = 49) eyedrops (2:1 ratio) instilled nightly over 24 months (mean index age = 12.2 ± 2.5 and 11.2 ± 2.8 years, respectively). Outcome measures were the changes in spherical equivalent (SE) and axial length (AL) from baseline. Results: At 12 months, the mean SE and AL change from baseline were −0.31D (95% confidence interval [CI] = −0.39 to −0.22) and 0.16 mm (95%CI = 0.13–0.20) in the atropine group and −0.53D (95%CI = −0.66 to −0.40) and 0.25 mm (95%CI = 0.20–0.30) in the placebo group (group difference p ≤ 0.01). At 24 months, the mean SE and AL change from baseline was −0.64D (95%CI = −0.73 to −0.56) and 0.34 mm (95%CI = 0.30–0.37) in the atropine group, and −0.78D (95%CI = −0.91 to −0.65) and 0.38 mm (95%CI = 0.33–0.43) in the placebo group. Group difference at 24 months was not statistically significant (p = 0.10). At 24 months, the atropine group had reduced accommodative amplitude and pupillary light response compared to the placebo group. Conclusions: In Australian children, 0.01% atropine eyedrops were safe, well-tolerated, and had a modest myopia-control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group. © 2022 The Authors. Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists.
Authors & Co-Authors
Lee, Samantha Sze Yee
Australia, Perth
The University of Western Australia
Lingham, Gareth
Australia, Perth
The University of Western Australia
Ireland, Dublin
Technological University Dublin
Blaszkowska, Magda K.
Australia, Perth
The University of Western Australia
Chia, Audrey Wi L.
Singapore, Singapore City
Singapore National Eye Centre
Singapore, Singapore City
Singapore Eye Research Institute
Loughman, James J.
Ireland, Dublin
Technological University Dublin
Flitcroft, Daniel Ian
Ireland, Dublin
Children's Health Ireland at Temple Street
Azuara-Blanco, Augusto
United Kingdom, Belfast
Queen's University Belfast
MacKey, David A.
Australia, Perth
The University of Western Australia
Australia, Melbourne
Centre for Eye Research Australia
Australia, Hobart
University of Tasmania
Statistics
Citations: 27
Authors: 8
Affiliations: 9
Identifiers
Doi:
10.1111/ceo.14148
ISSN:
14426404
Research Areas
Health System And Policy
Maternal And Child Health
Study Design
Cohort Study